A t the University of Pittsburgh, I teach a graduate-level course 'The Practical Analysis of High-Throughput Genomic and Proteomic Data'. 50% of the course grade is based on a paper project based on the re-analysis of published data sets. The aim of the project is to encourage the comparative evaluation of different approaches to the various analytic tasks for -omic based biomarker studies. The students are empowered by this course to understand -and to see for themselves -that different approaches to normalization, feature selection, and disease prediction model (a) exist, and (b) differ in their apparent relative performance in helping to generate lists of therapeutic targets or disease prediction models. We also learn about various data standards, mostly from the perspective of data formats, which are critical to re-analysis based algorithm evaluation studies.
published study', because the study concluded that those covariates and factor were not signifi cant, and should be shared. Privacy issues do not exist after the data have been de-identifi ed, and so requests not honoured due to patient privacy concerns should not be given any credence.
Reported data from biomarker studies should include (a) the raw data straight from its technological source, (b) any specifi c clinical data used to derive a conclusion from a study; (c) the survivorship studies precise survivorship data points for each patient. Patient privacy regulations in place can be met with these data sharing requirements. Publishing researchers should be prepared to stand behind and defend their published knowledge claims by providing data. The consequences of failing to hold ourselves to the highest standards are dire; I recently read reviewer comments of a grant proposal (my own, so I can share) that essentially claimed that past 25 years of published studies on individual protein and RT-PCR biomarker studies are too full of noise to warrant pre selecting biomarkers from the literature. We must not be so intently focused on competing for priority scores that the products of our life sciences and biomedical research enterprise are automatically considered useless upon publication. A movement back to data sharing-with the understanding that not all fl awed studies represent breaches of ethics-would also facilitate follow-up modeling and algorithm development and evaluation efforts designed to help the fi eld progress, and to facilitate the overt comparative evaluation of alternative and new analytical approaches, which should make everyone's studies better over time.
If authors fail to respond to reasonable requests for the data that is used to support a conclusion in a published study, or if they place unreasonable institutionalized strictures and policies in place for data sharing (e.g., protracted data sharing proposal submission/ review processes), then informatics researchers should draft and send letters to the Editor of the journal in which they have published their conclusions requesting the data from the journal. Editors as well as authors have a responsibility for any negative attendant health consequences that works published in their journal might infl ict on the public, and ease of data sharing should be rule, not the exception. Editors have options for enforcement; they can always offer to withdraw a paper that the scientifi c community cannot fully evaluate if the authors fail to comply with data sharing requests. Editors and publishers, however, have little incentive to police the integrity of the studies they publish, and perhaps the reputation of their journals are safest if they engage in such discourse only as a matter of last resort. Published letters to the editors inquiring on the status of the data requests are in keeping with good practices within an open scientifi c research community. Letters to funding agencies are a possible last resort.
Results reporting standards are needed more than data standards. I cannot enumerate all possible or desirable standards in a brief editorial, and perhaps should not due so because my writing is not peer reviewed and may not represent the consensus of the biomarkers and research informatics community. I will restrict my consideration to one type of results reporting. It is all too common in studies that use survivorship as an outcome to demonstrate that the predicted groups exhibit statistically signifi cant survivorship curves. Any study that reports such a result should also be required to calculate and publish the ROC curves of each positive prediction made by a model that would lead to a change in the clinical treatment for any patient in the future. For example, a study that concludes that a treatment outcome prediction model works well because the difference in the predicted groups' (responsive, not responsive) survivorship curves is statistically signifi cant should also report estimates of the performance evaluation measures of each prediction type (e.g., SN, SP for 'responsive', SN, SP 'not responsive'). They should then calculate the expected number of patients per year in a clinical group that, if the assay and model were in fact used on all patients qualifi ed for the model, would suffer due to errors in the model. This step would go a long way to indemnify the medical practioners, kit manufacturers & insurance companies from litigation because the patient could then be informed of the full attendant risks in terms that they can understand. For example: "Of all of the people who could be given this test this year (4500), 1500 are expected to be told that they will respond to therapy. Of these 1500 patients, 35 are expected to not respond to therapy in spite of their prediction. Similarly, 3500 patients expected to be told that they might not respond to therapy. Of these 3500, 600 may in fact respond to therapy in spite of their prediction. You may or may not fall into either category of erroneously diagnosed patients and the risks for you, as an individual patient, are estimated as...". Error rates on percentages will be useful for some patients, but some patients may not be able to envision that risk in terms of number of people per year. The full impact on the health of our population would also be made obvious with such simple reporting standards. This should empower the FDA to make more rapid conclusions about approval of a drug or an assay for clinical use, and for health care administrators to make informed decisions based on cost/benefi t analysis grounded on real data.
Given the brevity of the treatment of these topics, I invite short papers on Publication Reporting Standards to Cancer Informatics.
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